The phenomenon of accommodation in recipients of blood group ABO incompatible kidney transplantation (iKTx), in which grafts survive despite the presence of blood group A or B antigen in the graft and the presence of corresponding antibodies in the recipient's blood, is not uncommon. α1,3-N-Acetylgalactosaminyltransferase and α1,3galactosyltransferase associated with the synthesis of blood group A and B antigen (A and B enzymes), respectively, were measured by a highly specific enzymelinked immunosorbent assay in the sera and transplanted tissues of patients who underwent an ABO iKTx. Allogeneic A and B enzymes were present in the sera and tissues as well as A and B antigens in the tissues for a long period, which hitherto have never been seen in recipients prior to an iKTx. However, activities of these enzymes in the sera after an iKTx decreased in patients who experienced a serious acute antibody-mediated rejection and disappeared in patients who had an unrepairable rejection, leading to graft loss without establishment of accommodation. Our observations on the presence of allogeneic A and B enzymes in the recipients' sera should have implications in decision making for a successful iKTx.
The phenomenon of accommodation in recipients of blood group ABO incompatible kidney transplantation (iKTx), in which grafts survive despite the presence of blood group A or B antigen in the graft and the presence of corresponding antibodies in the recipient's blood, is not uncommon. α1,3-N-Acetylgalactosaminyltransferase and α1,3galactosyltransferase associated with the synthesis of blood group A and B antigen (A and B enzymes), respectively, were measured by a highly specific enzymelinked immunosorbent assay in the sera and transplanted tissues of patients who underwent an ABO iKTx. Allogeneic A and B enzymes were present in the sera and tissues as well as A and B antigens in the tissues for a long period, which hitherto have never been seen in recipients prior to an iKTx. However, activities of these enzymes in the sera after an iKTx decreased in patients who experienced a serious acute antibody-mediated rejection and disappeared in patients who had an unrepairable rejection, leading to graft loss without establishment of accommodation. Our observations on the presence of allogeneic A and B enzymes in the recipients' sera should
Introduction
Owing to recent advances in immunosuppressive therapies, ABO incompatible kidney transplantations (iKTx) have been successfully performed Takahashi and Saito 2006; Takahashi 2007a; Tanabe 2007; Genberg et al. 2008; Montgomery et al. 2009; Takahashi et al. 2010) . In many cases, no graft loss due to an acute antibody-mediated rejection (AMR) occurred even though incompatible A and/or B antigen is known to be present on the vascular endothelial cells within the graft (Takahashi 2007b) . This clinical condition has been called establishment of "accommodation" after incompatible organ transplantation (Hanto et al. 2003; Takahashi 2004) . To better understand this phenomenon, it is essential to investigate the fate of antigenicity in the transplanted graft comprising mainly blood group A and B antigens that are exposed in critical situations such as presence of anti-A and anti-B antibodies.
Human blood group ABH antigens are present not only on red blood cell membranes but also in tissues and body fluids (Daniels 1995) . The antigenic determinants of blood group A, B and H antigens commonly expressed on glycoproteins and glycolipids have been determined and their biosynthetic pathways have been described. The determinants of A and B blood groups are synthesized from the precursor, H substance by α1,3N-acetylgalactosaminyltransferase (A enzyme) and α1,3galactosyltransferase (B enzyme) in A and B blood group subjects, catalyzing the transfer of an N-acetylgalactosamine (GalNAc) or a galactose (Gal) to the H-active structure (Fucα1,2GaβR) in the presence of uridine diphosphate (UDP)-GalNAc or UDP-Gal, respectively (Daniels 1995; Watkins 1995) .
Glycosyltransferases including blood group A and B enzymes are primary products of glyco-genes and a large numbers of these have been cloned recently (Yamamoto et al. 1990; Watkins 1995) . Genomic background to express ABO blood group antigens as secondary products of the A and B genes in tissues and on red blood cells has also been studied (Daniels 1995; Watkins 1995) . Thus, blood group A and B phenotypes are commonly distinguishable by detecting A and B enzymes as well as A and B antigens. Further, the level of enzyme activity corresponds to the antigenic strength of A and B antigens, but some discrepancy has also been reported in their subgroups, variants and paraBombay individuals (Yazawa et al. 1993; Daniels 1995; Watkins 1995) .
A and B enzyme activities have been studied in patients who underwent bone marrow or solid organ transplantation (Yoshida et al. 1980; Barbolla et al. 1988; Matsue et al. 1989; Rydberg and Samuelsson 1991) . However, the transferase activities in the transplanted tissues were hardly detected in recipients' sera after solid organ transplantation probably due to the loss of enzyme activity, low sensitivity of assay or presence of an inhibitor and an antibody to serum glycosyltransferases (Barbolla et al. 1988; Matsue et al. 1989; Mojena and Bosca 1989; Kominato et al. 1990; Rydberg and Samuelsson 1991) . Previously, we synthesized H disaccharide attached to hydrophobic aglycones (Fucα1,2Galβ-OR) for assaying the A enzyme in plasma samples from various blood group A types and found that H disaccharides with hydrophobic aglycones were good acceptors for A enzymes not only from common types but also from variants with very weak enzyme activities (Yazawa et al. 1992 ). Further, blood group A and B enzyme activities of serum samples from subgroups, variants as well as from normal individuals could be measured quantitatively by an enzyme-linked immunosorbent assay (ELISA) consisting of synthetic H disaccharide immobilized silica beads (Synsorb H disaccharide) as an acceptor and synthetic A and B trisaccharides immobilized silica beads (Synsorbs A and B) as a standard for quantifying the products (Yazawa et al. 1993) . Additionally, we developed a sandwich-type immunoradiometric assay method for quantifying α1,3fucosyltransferase activities in serum samples by using a chemically synthesized oligosaccharide attached to bovine serum albumin (BSA) as an acceptor (Tachikawa et al. 1991) , and subsequently, a highly sensitive ELISA method by using the same H-active disaccharide attached to BSA was developed to measure blood group A and B enzymes, which allowed specific detection of weak enzyme activities in subgroups and variants of blood group A and B individuals (Seno et al. 1997) .
In the present study, A and B enzyme activities in sera and the transplanted tissues of the recipients who underwent ABO iKTx were investigated together with the immunohistochemical analysis of the A and B antigens in the graft to see the fate of A and B antigens in the donors. At the same time, the enzyme activity was investigated in patients with ABO compatible kidney transplantation (KTx).
Results

Demographic characteristics of patients
Demographic features of the 27 patients in this study are presented in Table 1 . All patients who underwent an iKTx or KTx have survived. Twenty-five cases with transplanted grafts (cases 1 to 20 and 23 to 27) have functioned well albeit suffering from rejections to varying degrees during this study, but without any graft loss. In patients with an iKTx, only three (cases 10, 21 and 22) suffered from an acute AMR due to anti-A or anti-B antibody; cases 21 and 22 experienced graftectomy on day 10 after the iKTx. Detection of A and B enzymes in sera and grafts of patients who underwent an iKTx After an iKTx, blood group A and B enzymes were detected in the sera of cases 1 to 10 at 1 week and in cases 11 to 22 at the time points indicated in Table 2 . A and B allogeneic enzymes were detected in all the recipients' sera except in one patient (case 13), and no discrepancy was seen between the blood groups of the graft tissues and the corresponding A and B enzymes. Serum A and B enzyme activities detected in the recipients after an iKTx were found to be significantly (P < 0.05) low as compared to those of the healthy controls, 278.3 and 1032.2 U/mL, respectively (n = 40, in each group). Further, consistent A and B enzymes were detected in serum samples at 1 week in cases 23 to 27 after a KTx (Table 2) as well, but no significant increase in A or B enzyme activity was observed in these patients. No significant correlation was found between the mass of the transplanted grafts and enzyme activities in the recipients' sera (Tables 1 and 2 ). In the two patients (cases 21 and 22) who suffered from an acute AMR resulting in the graft loss, A and B enzymes were detected after iKTx but their activities reduced soon after a serious acute AMR (described below). Levels of the A and B enzyme activities in patients with a KTx were calculated to be approximately 30 and 10 times, respectively, higher than those in patients with an iKTx irrespective of the mass of the graft or total ischemic time, indicating that these significantly (P < 0.05) high values found in cases 23 to 27 reflected autologous A and B enzyme activities (Table 2) . Likewise, the A and B enzymes could be detected in biopsies from the graft tissue after an iKTx (cases 3, 4, 8 and 9) as well as after KTx (cases 23 to 27) up to 2 months postoperation ( Table 2) .
Detection of A and B blood group antigens in the grafts with iKTx
The expression of A and B blood group antigens has been found in biopsy specimens of the transplanted graft. The presence of A antigen was clearly detected in the endothelial cells of the glomerular, artery, vein and peritubular capillary and epithelial cells of tubules (collecting duct and convoluted distal tubules) from case 10 whose blood group was type B and transplanted tissue was type A ( Figure 1A ). Similar patterns of positive immunostaining with anti-A and anti-B antibodies were also observed in the biopsy specimens from cases 7 and 20 at 4 and 6 years after an iKTx, respectively (Figure 1B and C) . No clear change in the distribution or strength of A and B antigens in the transplanted graft was seen during our observation period in patients with an iKTx or KTx, and no discrepancy was seen between blood group A and B antigens detected in the graft and A and B enzymes in the recipients' sera (Table 2) . Follow-up of serum antibodies, creatinine and A and B enzymes in patients with iKTx To investigate the relationship between the levels of biomarkers (anti-A and anti-B antibodies, creatinine, allogeneic serum A and B enzymes) and the fate of transplanted grafts, followup studies were done in 12 cases with iKTx (1 to 10, 21 and 22). The incompatible transplanted tissues (cases 1 to 10) seemed to function without graft loss and no serious AMR was observed except case 10. The profiles of these nine cases (cases 1 to 9) showed similar patterns with continuous detection of increased A or B enzyme activities which hitherto have never been detected in serum prior to operation, and levels of anti-A or anti-B antibody titers and creatinine were extremely low and no significant rebound was observed as in the case 6 (Figure 2) . Whereas, allogeneic A enzyme was also detected in case 10 on day 6 after operation ( Figure 3A) . In this case, titers of IgM anti-A were fairly high before operation but significantly decreased after twice receiving double filtration plasmapheresis (DFPP). However, the titers rebounded again up to 1:32 together with a rise in creatinine, and conversely, the activity of A enzyme dropped to 0.6 U/mL on day 14. Further, after three times of plasmaphereses, the anti-A-mediated rejection seemed to subside and the levels of antibody titers and creatinine significantly decreased and A enzyme activity restored and gradually increased up to 6.3 U/mL at 2 months after iKTx. Under these conditions, the transplanted tissue seemed to function without graft loss ( Figure 3A) . Therefore, no graft loss occurred in all the patients except cases 21 and 22 who underwent an iKTx along with the detection and preservation of allogeneic A and B enzymes in the recipients' sera resulting from the establishment of accommodation. To further understand the application of this work and to design strategies for successful iKTx, allogeneic A and B enzymes were also measured in cases 21 and 22 who received an iKTx but experienced graft loss. The anti-A-mediated rejection was observed in case 21 in which allogeneic A enzyme was detected on day 4 after iKTx ( Figure 3B ). In this case, titers of IgM and IgG antibodies were very low before and after operation. However, activities of serum A enzyme decreased along with a rapid elevation of IgM antibody titers, which reached the background level on day 17 with graftectomy on day 10. In contrast, anti-B-mediated rejection was observed in case 22 in which allogeneic B enzyme was found on day 5 after iKTx ( Figure 3C ). Titers of IgG anti-B antibody were exceptionally high (1:128) before operation and decreased up to 1:16 at an iKTx by the aforementioned treatment with DFPP and plasmaphereses. However, on day 10 after operation the titers gradually increased up to 1:128, no serum B enzyme activity was detected and then the graftectomy was conducted. In these cases with a serious AMR, allogeneic A and B enzyme activities, once detected in sera after iKTx, were found to decrease rapidly and disappear without establishment of accommodation resulting in the graft loss, suggesting that once unrepairable rejections occur, the allogeneic enzymes should not continue to be present.
Discussion
ABO incompatible organ transplantation has become successful reflecting recent advances in immunosuppressive therapy and the innovations to remove antidonor antibodies from the Fig. 2 . Levels of antibody titers, serum creatinine and allogeneic B enzyme activities changed before and after iKTx. Activities of B enzyme in sera from the case 6 whose blood group was type A were measured together with levels of serum creatinine, titers of IgM and IgG antibodies, respectively. D, DFPP. Fig. 3 . Levels of antibody titers, serum creatinine and allogeneic A or B enzyme activity in patients with iKTx who suffered from an acute AMR. Three patients received from an acute AMR after iKTx but the case 10 (A) recovered with the continuous detection of A enzyme activities. Cases 21 (B) and 22 (C) experienced a serious AMR resulting in the decrease of allogeneic A or B enzyme activity and graft loss. Graftectomy was conducted in these two cases on day 10 after operation. D, DFPP; E, plasma exchange; G, graftectomy.
Detection of allogeneic enzymes in recipients after ABO iKTx circulation of the recipients (Galili 2006; Takahashi and Saito 2006; Takahashi 2007a; Takahashi 2007b; Genberg et al. 2008; Montgomery et al. 2009; Takahashi et al. 2010 ). There still remains a significant challenge to perform organ transplantation of ABO incompatible cases across the ABO blood groups barrier, but as previously reported, outcomes from therapy in kidney transplantation showed no statistically significant difference in 10-year , 3-year (Genberg et al. 2008) and 5-year (Montgomery et al. 2009; Takahashi et al. 2010 ) graft survival rates between ABO compatible and incompatible transplantation. In line with these assertions, in this study, up to now, no graft loss has occurred in patients with an iKTx or with KTx who continue showing allogeneic A and/or B enzyme activities in their sera.
Even though some patients with a successful iKTx experienced clinical and/or pathological rejections for a while, only one patient (case 10) suffered an AMR in this study which might induce a serious response after operation (Takahashi 2007a ). Antibodies of both IgM and IgG in case 10 were efficiently removed by twice DFPP, but pathological changes developed gradually and progressed in the critical period resulting from a rapid elevation of IgM antibody titers which is defined as the time between 2 and 7 days after transplantation (Takahashi 2007a) . Further, elevation of IgM antibody occurred without an elevated IgG antibody titer, but the level was fairly low.
Measurement of allogeneic A and B enzymes in serum and graft tissues showed that enzyme activities could be detected in 24 cases with successful iKTx but no A enzyme activity was found in case 13 at 14 years after an iKTx. The presence of inhibitor and/or antibody against A and B enzymes has been reported in sera from patients with ABO incompatible transplantation (Barbolla et al. 1988; Matsue et al. 1989; Mojena and Bosca 1989; Kominato et al. 1990; Rydberg and Samuelsson 1991) . When normal A and B sera from healthy volunteers were incubated with serum from case 13, their A and B enzyme activities were inhibited depending on the amount of serum added (data not shown). Therefore, it was assumed that the serum of case 13 contained an inhibitor and/or antibody against A/B enzyme after an iKTx.
Levels of allogeneic A and B enzyme activities in sera of recipients with iKTx were quite low in comparison with those in normal serum of each blood group as an autologous enzyme. In fact, A and B enzyme activities in sera from cases 23 to 27 showed almost the same activity as those in sera from common A and B blood types (Seno et al. 1997) . It is likely that A and B enzymes were diluted with their own blood after secreting from the graft tissues and this caused a reduction in enzyme activities. The same dilution of enzyme with large amounts of circulating blood was also observed in our previous study when α1,3fucosyltransferase originating from the tumor tissues was detected in serum (Asao et al. 2001) .
Follow-up studies on the levels of antibody and serum enzyme activities showed that antibody titers were reduced up to less than 1:4 in most cases with the help of preoperative removal of antidonor antibody. However, in cases 10, 21 and 22 with an acute AMR whose antibody titers changed differently after operation, higher titers of antidonor antibody must affect the function of the graft tissue and the expression of blood group antigens on the endothelium potentially damaging the serum enzyme that is secreted by the tissue during this time. It was therefore likely that the reduction and then restoration of enzyme activities reflected such immune reactions, and no restoration seemed to result from a sudden and dramatic increase of anti-A or anti-B antibody titers in recipients.
Molecular cloning of blood group A and B enzymes enabled us to determine the presence and characterization of ABO genes by using blood and tissue specimens without assaying their products, namely A and B enzyme activities. Results from semi-quantitative reverse transcription polymerase chain reaction for the A and B enzymes by using mRNA isolated from biopsy specimens before and after iKTx showed almost the same expression of A and B enzymes and no significant difference was found in their mRNA levels (data not shown). Enzymatic and immunohistochemical analyses as well as molecular studies clearly indicated that serum A and B enzymes were continuously secreted by the graft in cases with no graft loss and that mismatched antigens could be synthesized for a long period in the transplanted renal tissue. To further support these observations, A and B enzyme activities were detected in sera and biopsy specimens after iKTx procedures, but the enzyme activities fell sharply after a serious AMR and disappearance of the activity after graftectomy indicated that the allogeneic enzymes originated from the donors' grafts.
It is thought that the accommodation as has been defined (Takahashi 2007a; Takahashi 2007b ) must be induced in all cases with a minor time difference. The expression of A and B blood group antigens in the graft tissue is not regulated by the recipients' glyco-and immune-system, but the transplanted organ is living, unaffected by the major-mismatched blood group system in the recipients. Therefore, the term "accommodation" includes a stable presence of allogeneic A and B enzymes in recipients' sera. It is highly recommended to measure these enzymes with a specific and sensitive ELISA like the system we used in this study, consisting of detection of newly synthesized A-and B-active structures by A and B enzymes in the sera and graft tissues by using corresponding antibodies. We have ascertained that our method for measuring synthesized A and/or B antigens by an ELISA should be applicable for measuring enzyme activities with no effect of anti-A and anti-B antibodies present in recipient's sera used as an enzyme source. The strategy for measuring allogeneic A and B enzyme activities with the same ELISA method was also found to be quite valuable for verifying successful incompatible bone marrow transplantation (authors' unpublished observations). During this study, levels of the A enzyme seemed to be fairly low in comparison with those of B enzyme as measured by the present ELISA. However, as different units were used for definition of A and B enzyme activities and anti-A and anti-B monoclonal antibodies used in the present ELISA have different reactivity towards the synthesized A-and B-active structures, it is not logical to compare the enzyme activities here.
In our recent study, blood group A-and B-active molecules were isolated from human kidney tissues, and it was demonstrated that those consisted mainly of N-linked glycoproteins were localized in the vascular endothelial cells (Tasaki et al. 2009 ). Blood group A and B antigens found in the transplanted graft tissues seemed to maintain the same characteristics for a long period of time. Our work on these continues.
In conclusion, our observations on the presence of blood group A and B enzyme activities both in the sera and in the trans-planted tissues of recipients that coincided with the survival of the same type of A and B antigens in the transplanted graft should have implication in the decision making for a successful iKTx. Likewise, potentially, this work should have application in designing strategies for successful iKTx and establishment of accommodation as allogeneic A and B enzyme activities ceased and did not restore after an unrepairable rejection. Therefore, the disappearance of allogeneic serum A and/or B enzyme after an iKTx could be induced not only by graftectomy but also by the failure to establish accommodation, and the graft loss mainly caused by a serious acute AMR. Regarding the relationship between the fate of allogeneic A and B enzymes and the establishment of accommodation as well as the effects of DFPP and/or plasmapheresis, it remains to be seen if increasing the number of test samples from patients with an iKTx can further strengthen the current level of knowledge. However, with such progress in hand, it should be possible to predict establishment of accommodation after an iKTx, which could be a major step forward for successful iKTx. During the last 17 years, we have carried out 58 iKTx procedures in our hospital, and only 4 cases (6.9%) suffered graft loss due to an AMR. However, no graft loss has been experienced during the last 6 years (30 cases are completed). Likewise, no AMR has occurred in our patients during the last 3 years (12 cases are completed; authors' unpublished data). Accordingly, it has become rare to see a case with graft loss due to a severe AMR after an iKTx. To our knowledge, this is the first report demonstrating the presence of allogeneic A and B enzymes in the sera and tissues of recipients after an iKTx.
Materials and methods
UDP-GalNAc, UDP-Gal, BSA, Triton X-100 and Tween 20 were obtained from Sigma (St. Louis, MO). Proculin was from Zymed (South San Francisco, CA). A 96-well microtiter plate (Maxisorb) was from Thermo Fisher Sci. (Rochester, NY). Hog and goat sera were purchased from Irvine Scientific (Santa Ana, CA) and Invitrogen (Tokyo, Japan), respectively. DAKO TMB Blue Substrate-Chromogen Ready-to-Use and horseradish peroxidase (HRP)-conjugated goat antimouse Ig antibody were obtained from DAKO (Carpinteria, CA). Anti-A and anti-B antibodies for immunostaining of tissues were obtained from Ortho Diagnostic Systems, Tokyo, Japan. All other reagents were of the highest grade commercially available. Sera from volunteer healthy controls with A, B, O and AB blood groups, 20 in each case, were prepared.
Clinical background of patients Serum and biopsy samples were obtained from patients who underwent ABO iKTx and KTx at Niigata Medical and Dental Hospital, Niigata, Japan. Ten of the 27 patients (cases 1 to 10) had received an iKTx and 5 (cases 23 to 27) had received KTx between April 2006 and July 2008 and 10 patients (cases 11 to 20) underwent iKTx between 1994 and 2005 had a fairly long graft survival time. Two patients (cases 21 and 22) had received an iKTx but experienced a graft loss. Details of immunosuppressive therapies in these patients have been described elsewhere and are summarized in Table 1 . Protocol renal graft biopsies to verify the subclinical damages and rejection were done before and after iKTx (Rush et al. 1998 ).
Episode renal graft biopsies that were performed to analyze the renal dysfunction were done when appropriate. In all the cases, samples from the biopsy were fixed in 10% buffered formalin and embedded in paraffin for histological examinations. The diagnostic criteria for AMR were based on the morphologic features of the Banff 07 classification (Solez et al. 2008) . During this study, we conducted 51 iKTx and experienced only 3 cases with graft loss (5.9%) mainly due to AMR, two of those (cases 21 and 22) were described here. This study was approved by the Ethics Committee of Niigata University, Faculty of Medicine. Likewise, the study was performed in accordance with the Guidelines of the Declaration of Helsinki. Informed consent was obtained from all patients prior to the initiation of the study.
ELISA for A and B enzymes
Blood group A and B enzyme activities were measured by an ELISA as described previously (Seno et al. 1997 ) with a slight modification. Each well of a 96-well microtiter plate was coated with a 0.1 μg of H disaccharide covalently attached to BSA (Fucα1,2Galβ-(CH 2 ) 8 -CO-BSA) per each well as an acceptor and was blocked with 0.02 M phosphate-buffered saline (PBS), pH 7.0 containing 1% BSA and 5% sorbitol at 4°C overnight and dried at 25°C. The plate stocked at 4°C was first washed with 350 μL of the washing buffer containing 2.7 mM KCl, 8.1 mM NaH 2 PO 4 12H 2 O, 0.14 M NaCl, 1.5 mM KH 2 PO 4 and 0.05% Tween 20. The standard reaction mixture for A enzyme contained 50 μL of A-buffer (50 mM N-2-hydroxyethylpiperazine-N′-4-butanesulfonic acid (HEPES), 40 mM MnCl 2 , 0.4% Triton X-100, 20 mg/mL BSA, 20% inactivated porcine serum, pH 6.5), 50 μL of UDP-GalNAc (0.4 mg/mL in 50 mM HEPES) and 10 μL of serum sample. The reaction mixture for B enzyme contained 50 μL of B-buffer (50 mM HEPES, 40 mM MnCl 2 , 0.4% Triton X-100, 78.7 mM NaCl, 1.3 mM ATP, 20 mg/mL BSA and 20% inactivated porcine serum, pH 6.5), 50 μL of UDP-GalNAc (0.4 mg/mL in 50 mM HEPES) and UDP-Gal (0.4 mg/mL in 50 mM HEPES) and 10 μL of serum sample. After adding the reaction mixture to each well, the plate was incubated at 25°C for 90 min. The plate was then washed five times with 350 μL of the washing buffer, and then, 100 μL of HRP-conjugated anti-A (for A enzyme) and anti-B (for B enzyme) antibodies was added and incubated at 25°C for 60 min. After washing the plate five times with 350 μL of the washing buffer, 100 μL of the TMB solution (DAKO) was added to each well following incubation at room temperature for 15 min. The increase in absorbance at 450 nm was monitored after addition of 100 μL of 1 N H 2 SO 4 solution to each well. The standard curves of A and B enzymes were obtained by using standard enzymes prepared from pooled A and B plasma samples with activities determined as 450 U/mL. A unit of A and B enzyme activity was defined arbitrarily as the quantity of enzyme incorporating 1.1 pmol of GalNAc and 32 fmol of Gal into the H disaccharide at 25°C for 1 h, respectively, calculated based on the amounts of GalNAc and Gal residues incorporated into H disaccharide using radio-active UDP-[ 3 H]GalNAc and/or UDP-[ 3 H]Gal and the standard enzymes as described previously (Yazawa et al. 1992) . When graft tissues were used as enzyme source, biopsy samples were solubilized in 200 μL of PBS containing 2% Triton X-100 by sonication at 4°C, and the mixture was centrifuged at 10,000 rpm for 10 min, and the supernatant was used for assay. A unit of A and B enzyme activity was also defined as the same quantity in case of serum per mg protein of the tissue. Protein concentration was determined with a DC-protein assay kit (Bio-Rad, Hercules, CA) using BSA as standard. Since nonspecific absorbance was seen in the plate for A and B enzymes with samples from blood type O sera as enzymes (n = 20), enzyme activity was determined after subtraction of 2.6 U/mL (A enzyme) and 7.3 U/mL (B enzyme) from the observed values, which was obtained as the mean + 2 S.D., respectively.
Immunohistochemical staining of tissues
The deparaffinized sections were incubated for 1 h with anti-A and anti-B antibodies. After washing with PBS, the sections were incubated for 1 h with HRP-conjugated goat anti-mouse Ig antibody. Color was developed with a solution containing 0.05% of 3,3′-diaminobenzidine tetrahydrochloride and 0.01% hydrogen peroxide in 0.05 M Tris-Cl buffer (pH 7.6). The sections were then counterstained with hematoxylin, washed with distilled water and mounted.
